11 results
Primary Objective:To assess whether the clinical efficacy of RPC1063 is superior to interferon (IFN) *-1a (Avonex®) inreducing the rate of clinical relapses in patients with RMS.Secondary Objectives:- To assess the effect of RPC1063 on the…
To assess whether there is (cost) effectiveness over a period of 1 year of additive intra-articular injections with a high molecular HA derivate in patients with OA of the knee.
To validate the results from two RCTs that SCS is indeed capable of treating otherwise refractory diabetic neuropathic pain, and to evaluate the effects of burst stimulation settings in this patient group.
To evaluate whether dGEMRIC is suitable as outcome measure to detect changes over time, and also between intervention groups in patients with OA of the knee.
To demonstrate that SCS is capable of treating otherwise refractory neuropathic pain after chemotherapy / radiotherapy.
To evaluate the long-term safety and efficacy of RPC1063 for the treatment of all patients with moderate to severe UCTo evaluate the long-term efficacy of RPC1063 for the treatment of adult patients with moderate to severe UC.
To evaluate and quantify the various clinical effects of closed-loop SCS versus open-loop SCS on the underlying pathophysiological effects in CRPS.
The objective of this study is to assess the feasibility of SCS using the Wavewriter Alpha for control of treatment resistant endometriosis-related pain symptoms
Primary Objective:- Demonstrate the efficacy of ozanimod compared to placebo on the maintenance of clinical remission and endoscopic responseSecondary Objectives:- Demonstrate the efficacy of ozanimod compared to placebo on maintenance of clinical…
Primary objective:- Demonstrate the efficacy of ozanimod compared to placebo on the induction of clinical remissionSecondary objectives:- Demonstrate the efficacy of ozanimod compared to placebo on induction of clinical response, clinical remission…
The objective of this study is to demonstrate the long-term safety and explore tong-term efficacy of ozanimod for the treatment of subjects with moderately to severely active CD.